Biotest Aktiengesellschaft (BIESF)
USD 30.48
(0.0%)
USD 30.48
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.7 Million | -40.5 Million | 33.9 Million | -16.7 Million | -33.6 Million | -50 Million |
| Net Income | 127 Million | 31.7 Million | -63.4 Million | -30 Million | -1.3 Million | -6 Million |
| Depreciation & Amortization | 35.9 Million | 35.8 Million | 31.1 Million | 29.6 Million | 31.7 Million | 24.7 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -120.8 Million | -45.2 Million | 21.5 Million | -32.8 Million | -59.3 Million | -79.5 Million |
| Other non-cash items | -44.8 Million | -62.8 Million | 44.7 Million | 16.5 Million | -4.7 Million | 10.8 Million |
| Investing Cash Flow | 1.3 Million | -37 Million | -23.4 Million | -14.6 Million | -8 Million | 200.8 Million |
| Investments in PPE | -33.4 Million | -29.3 Million | -18.2 Million | -27 Million | -34.1 Million | -54.6 Million |
| Acquisitions | 35 Million | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | 11.5 Million | 18.4 Million | - |
| Other Investing Activities | -300 Thousand | -7.7 Million | -5.2 Million | 900 Thousand | 7.7 Million | 255.4 Million |
| Financing Cash Flow | -6.8 Million | 89.6 Million | 22.6 Million | 42 Million | 40.5 Million | -111.2 Million |
| Debt repayment | -12 Million | -5.8 Million | -5.3 Million | -2.5 Million | -4 Million | -595.2 Million |
| Dividends payments | - | -800 Thousand | -800 Thousand | -800 Thousand | -800 Thousand | -800 Thousand |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 2.1 Million | 96.2 Million | 28.7 Million | 45.3 Million | 45.3 Million | 484.8 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | -165.7 Million | -76.1 Million | 23.8 Million | -29.9 Million | -44.3 Million | -90.7 Million |
| Other working capital | 44.9 Million | 30.9 Million | -2.3 Million | -2.9 Million | -15 Million | 11.2 Million |
| Cash at beginning of period | 116.6 Million | 104.4 Million | 71.3 Million | 60.8 Million | 61.9 Million | 22.3 Million |
| Cash at end of period | 108.1 Million | 116.6 Million | 104.4 Million | 71.3 Million | 60.8 Million | 61.9 Million |
| Capital Expenditure | -33.4 Million | -29.3 Million | -18.2 Million | -27 Million | -34.1 Million | -54.6 Million |
| Effect of forex changes on cash | 100 Thousand | 100 Thousand | - | -200 Thousand | - | - |
| Net cash flow / Change in cash | -8.5 Million | 12.2 Million | 33.1 Million | 10.5 Million | -1.1 Million | 39.6 Million |
| Free Cash Flow | -36.1 Million | -69.8 Million | 15.7 Million | -43.7 Million | -67.7 Million | -104.6 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 9.7 Million | 29.5 Million | 38.6 Million | 127 Million | 114.4 Million | -5.6 Million |
| Depreciation & Amortization | 21.7 Million | - | 35.8 Million | 35.9 Million | -17.7 Million | 17.7 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 28 Million | -64 Million | 58.5 Million | -120.8 Million | -97.7 Million | -57.3 Million |
| Other non-cash items | 20.7 Million | 22.9 Million | -66.6 Million | -44.8 Million | 6.8 Million | 7.7 Million |
| Investing Cash Flow | -4.6 Million | -9.9 Million | -12.1 Million | 1.3 Million | -6 Million | 29.6 Million |
| Investments in PPE | - | - | -33.4 Million | -33.4 Million | - | - |
| Acquisitions | - | - | - | 35 Million | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -4.6 Million | -9.9 Million | 21.3 Million | -300 Thousand | -6 Million | 29.6 Million |
| Financing Cash Flow | -72.3 Million | -1.9 Million | -11.6 Million | -6.8 Million | 7.3 Million | -1.2 Million |
| Debt repayment | - | - | - | -12 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -72.3 Million | -1.9 Million | -11.6 Million | 2.1 Million | 7.3 Million | -1.2 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | -165.7 Million | -165.7 Million | - | - |
| Other working capital | 28 Million | -64 Million | 224.2 Million | 44.9 Million | -97.7 Million | -57.3 Million |
| Cash at beginning of period | 84.8 Million | 108.1 Million | 65.4 Million | 116.6 Million | 58.3 Million | 68 Million |
| Cash at end of period | 66.3 Million | 84.8 Million | 108.1 Million | 108.1 Million | 65.4 Million | 58.3 Million |
| Capital Expenditure | - | - | -33.4 Million | -33.4 Million | - | - |
| Effect of forex changes on cash | - | 100 Thousand | 500 Thousand | 100 Thousand | -400 Thousand | -200 Thousand |
| Net cash flow / Change in cash | -18.5 Million | -23.3 Million | 42.7 Million | -8.5 Million | 7.1 Million | -9.7 Million |
| Free Cash Flow | 58.4 Million | -11.6 Million | 32.9 Million | -36.1 Million | 5.8 Million | -37.5 Million |
I8R
9369
196170
ASCB
6323
9827